Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.
相关临床试验
44
28 进行中
药物批准
2
批准总数
监管机构
1
监管机构数
成立时间
2008
进行中（未招募）
26
59.1%
已完成
6
13.6%
Enrolling By Invitation
1
2.3%
尚未招募
1
2.3%
招募中
8
18.2%
终止
1
2.3%
Unknown
1
2.3%
- Vir Biotechnology appointed Timothy Coughlin, former CFO of Neurocrine Biosciences, to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. - Coughlin brings extensive experience guiding companies from clinical-stage to fully integrated commercial enterprises, including navigating regulatory setbacks. - The appointment comes as Vir advances its potential best-in-class treatment for chronic hepatitis delta and its pipeline of masked T-cell engagers for solid tumors. - Coughlin currently serves on the boards of aTyr Pharma, ADC Therapeutics, and Travere Therapeutics, and previously served on boards including Fate Therapeutics and Peloton Therapeutics.
- The FDA approved the first therapy for primary IgA nephropathy in December 2021, and since then multiple novel drugs have received accelerated approval, transforming the treatment landscape. - A 2016 Kidney Health Initiative partnership redefined surrogate endpoints, establishing proteinuria reduction at 9 months as an acceptable marker, which made clinical trials feasible and affordable. - Currently, five therapies are approved in the U.S., including sparsentan, atrasentan, budesonide, sibeprenlimab, and iptacopan, with additional agents like atacicept and povetacicept under FDA review. - Experts emphasize that despite the "embarrassment of riches" in therapies, early patient identification remains the biggest challenge, as many patients present too late for optimal intervention.
- The FDA has approved Zevra Therapeutics' Miplyffa for the treatment of Niemann-Pick disease type C, a rare neurodegenerative disorder. - This regulatory milestone marks a significant advancement in the treatment landscape for this progressive disease, offering new hope to patients. - Following the announcement, Zevra Therapeutics Inc. (ZVRA) experienced a surge in its stock price, reaching a new 52-week high. - The approval underscores the potential of Miplyffa to address the unmet medical needs of individuals affected by Niemann-Pick disease type C.
